OncoSec Medical Inc  

(Public, NASDAQ:ONCS)   Watch this stock  
0.990
0.000 (0.00%)
May 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.88 - 2.08
Open     -
Vol / Avg. 0.00/126,734.00
Mkt cap 20.14M
P/E     -
Div/yield     -
EPS -1.30
Shares 20.87M
Beta 2.28
Inst. own 9%
Jun 7, 2017
Q3 2017 OncoSec Medical Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 1, 2017
Q3 2017 OncoSec Medical Inc Earnings Call - 4:15PM EDT - Add to calendar
Mar 16, 2017
Q2 2017 OncoSec Medical Inc Earnings Call
Mar 16, 2017
Q2 2017 OncoSec Medical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -82.48% -79.09%
Return on average equity -99.72% -88.52%
Employees 46 -
CDP Score - -

Address

5820 Nancy Ridge Dr
SAN DIEGO, CA 92121-2842
United States - Map
+1-858-2107333 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.

Officers and directors

Avtar S. Dhillon M.D. Independent Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Punit S. Dhillon President, Chief Executive Officer, Director
Age: 36
Bio & Compensation  - Reuters
Richard B. Slansky Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Sheela Mohan-Peterson J.D. Chief Legal and Compliance Officer
Age: 54
Bio & Compensation  - Reuters
Sharron Gargosky PhD Chief Clinical and Regulatory Officer
Age: 52
Bio & Compensation  - Reuters
James Michael DeMesa M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Anthony E. Maida III, Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters